Since Dr. Huggins' 1941 Nobel prize winning finding that androgen deprivation therapy (ADT) effectively controls metastatic prostate cancer (PCa), 70 years passed before CHAARTED  and STAMPEDE  demonstrated that adding docetaxel to ADT prolongs survival in men with metastatic PCa. The de novo metastatic PCa global incidence is striking: 3% in the US, 6% across Europe, 4-10% in Latin America, and 60% in Asia-Pacific . Historically, ADT has been standard of care, however most men progress to metastatic castration-resistant prostate cancer (mCRPC). This article is protected by copyright. All rights reserved.
BJU international. 2017 Oct 09 [Epub ahead of print]
Zachary Klaassen, Declan G Murphy
Department of Surgery, Division of Urology, University Health Network, Princess Margaret Cancer Centre, Toronto, Ontario, Canada., Division of Cancer Surgery, Peter MacCallum Cancer Centre, Melbourne, Australia.